Show simple item record

dc.contributor.authorIbarra-Meneses, Ana Victoria 
dc.contributor.authorSanchez Herrero, Carmen 
dc.contributor.authorAlvar, Jorge 
dc.contributor.authorMoreno, Javier 
dc.contributor.authorCarrillo, Eugenia 
dc.date.accessioned2019-02-27T19:39:17Z
dc.date.available2019-02-27T19:39:17Z
dc.date.issued2017-09
dc.identifier.citationFront Immunol. 2017 Sep 29;8:1208.es_ES
dc.identifier.issn1664-3224es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7252
dc.description.abstractNew biomarkers are needed to identify asymptomatic Leishmania infection as well as immunity following vaccination or treatment. With the aim of finding a robust biomarker to assess an effective cellular immune response, monocyte chemotactic protein 1 (MCP-1) was examined in plasma from soluble Leishmania antigen (SLA)-stimulated whole blood collected from subjects living in a Leishmania infantum-endemic area. MCP-1, expressed 110 times more strongly than IL-2, identified 87.5% of asymptomatic subjects and verified some asymptomatic subjects close to the cutoff. MCP-1 was also significantly elevated in all patients cured of visceral leishmaniasis (VL), unlike IL-2, indicating the specific memory response generated against Leishmania. These results show MCP-1 to be a robust candidate biomarker of immunity that could be used as a marker of cure and to both select and follow the population in vaccine phase I-III human clinical trials with developed rapid, easy-to-use field tools.es_ES
dc.description.sponsorshipThe authors thank the Instituto de Salud Carlos III which provided funding via the ISCIII-AES project “Impact of a leishmaniasis outbreak in the southwest of Madrid in the immunosuppressed population” (PI13/00440) and via the projects RD12/0018/0003 and RD12/0018/0008 Red de Enfermedades Tropicales, Subprograma RETICS del Plan Estatal de I+D+I 2013-2016, co-funded by FEDER.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Mediaes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAsymptomatic infectiones_ES
dc.subjectBiomarkeres_ES
dc.subjectChemokineses_ES
dc.subjectCytokineses_ES
dc.subjectLeishmaniasises_ES
dc.subjectMonocyte chemotactic protein 1es_ES
dc.subjectTreatmentes_ES
dc.subjectWhole blood assayes_ES
dc.titleMonocyte Chemotactic Protein 1 in Plasma from Soluble Leishmania Antigen-Stimulated Whole Blood as a Potential Biomarker of the Cellular Immune Response to Leishmania infantumes_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID29033933es_ES
dc.format.volume8es_ES
dc.format.page1208es_ES
dc.identifier.doi10.3389/fimmu.2017.01208es_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fimmu.2017.01208es_ES
dc.identifier.journalFrontiers in immunologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI13/00440es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD12/0018/0003es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD12/0018/0008es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional